Skip to content

10.6 EMA matters

Return to January 2016 Board Agenda here.

PRIME consultation

Consultation here. EAHP response here.

Orphan Drugs

Report from Marc Dooms from December workshop here. Agenda here.

Clinical Trials

Both Roberto and Francesca Venturini continue to input to the development of new trial databases and portals under the remit of the EMA, as well as advise on relevant EMA clinical trial related consultations.

To also note a future EMA workshop on extrapolation of efficacy and safety in medicine development in May 2016. Information here. Francesca advises appropriate HP representation. 

Risk Minimisation

Among a number of working groups constructed by EMA through its stakeholder organisation is one focused on EMA’s activities around risk minimisation (e.g. communications) and assessment of their effectiveness. RP is currently the EAHP contact point in the working group. EMA are due to supply the group with some examples of such communications for members to comment on and review. Minutes of last teleconference here.

Shortages

EMA activity in the area of medicines shortages is covered in agenda item 10.2

EMA Leadership

Guido Rasi reinstated as Executive Director. Information here.

×

EAHP Forum

All the EAHP team is working on providing a Forum that can help connect all the members in Conversations and Groups to talk about important matters for the European Hospital Pharmacist.

The Forum will be accessible for all the EAHP members, you don’t have to create a new account to browse and participate.

Conversations and groups

The Conversations will be moderated by our team to provide documents and relevant topics for the community.

The Groups will connect all members that share a category. Members who work on the same assocation, on the same hospital, that have the same role, etc.

Stay tuned for the realase of the forum. Soon on EAHP.